Leptomeningeal Carcinomatosis of Gastric Cancer Misdiagnosed as Vestibular Schwannoma

Shin-Jae Kim, M.D., Jeong-Taik Kwon, M.D., Ph.D., Seog-Kyun Mun, M.D., Young-Ho Hong, M.D.
Departments of Neurosurgery, Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine, Seoul, Korea

Gastric cancer is one of the most common causes of cancer-related death in Asian countries, including Korea. We experienced a case of leptomeningeal carcinomatosis (LC) from gastric cancer that was originally misdiagnosed as vestibular schwannoma based on the similar radiological characteristics. To our knowledge, LC from gastric cancer is very rare. In conclusion, our experience with this case suggests that clinicians should consider the possibility of delayed leptomeningeal metastasis when treating patients with gastric cancer.

Key Words : Meningeal carcinomatosis - Leptomeningeal carcinomatoses - Carcinomatous meningitis - Signet ring cell carcinoma - Vestibular schwannoma - Neurofibromatoses.

INTRODUCTION

Leptomeningeal carcinomatosis (LC) is a metastatic malignant condition that involves the pia mater and arachnoid membrane. In adult malignancies, where LC occurs most commonly, the most common origin of LC is breast cancer, followed by lung cancer and melanoma, whereas among the pediatric malignancies, leukemia shows the highest incidence of LC. The prevalence of LC in these malignancies is estimated at approximately 5–8%. In addition, LC is reported to occur most frequently in malignancies such as breast cancer, lung cancer, leukemia, and lymphoma. In patients with gastric cancer, however, the prevalence is less than 0.16%. This implies that LC is not a rare disease entity. In Asian countries, particularly Korea and Japan, the prevalence of gastric cancer is relatively high compared to that in western countries, and the prevalence of LC has also been reported to be high compared with other countries. According to Tsujikawa et al., the prevalence of LC in cases of gastric cancer ranges from 1.7% to 5.5% in Japan.

In the case described here, the initial presentation or the location and shape of the lesions on magnetic resonance imaging (MRI) scans were suggestive of bilateral vestibular schwannoma. At that time, the patient was therefore suspected of having Type II neurofibromatosis. However, the patient presented with an aggravation of symptoms during follow up to monitor his clinical course, and the patient was ultimately diagnosed with LC on the basis of brain biopsy. To our knowledge, such cases of LC from gastric cancer are very rare. Here, we describe this case of a patient with LC from gastric cancer and review the relevant literature.

CASE REPORT

A 58-year-old man presented at the outpatient clinic of the department of otorhinology with a chief complaint of a sustained, sudden-onset bilateral hearing difficulty 4 months previously. The patient was hospitalized for further evaluation and treatment of bilateral sudden sensorineural hearing loss. Both tympanic membranes were intact. A Weber's tuning-fork test revealed no lateralization. A Rinne test was not performed because the patient did not provide consent for this procedure.

On pure tone audiometry, the patient had an air conduction threshold and bone conduction threshold of 38 dB and 35 dB, respectively, on the left side and 40 dB and 38 dB, respectively, on the right side. The patient was suspected to have bilateral vestibular schwannoma involving both inner ears based on T1-weighted temporal MRI scans (Fig. 1). We assumed that the patient was less likely to present with symptom aggravation in the
short term if he had bilateral vestibular schwannoma. Accordingly, the patient was scheduled to undergo outpatient short-term follow-up examinations, including brain MRI, after 3 months and was discharged. Four months later, at a visit for monitoring of the clinical course, the patient reported bilateral loss of hearing. The patient visited the hospital again with chief complaints of bilateral temporal headache, dizziness, vertigo, and vomiting. On physical examination, the patient showed no notable neurological deficits or neck stiffness in addition to hearing loss. An increase in the size of the lesions in both inner ears was detected on contrast-enhanced temporal MRI, accompanied by the presence of newly developed lesions in the cisternal segments, Meckel’s caves, and the left cerebellum (Fig. 2). The patient also complained of lower back pain. Thus, evaluation with whole-spine MRI was done which revealed multiple hyperintense lesions at the L1-L4 level of the spinal cord (Fig. 3).

The patient had been diagnosed with gastric cancer 2 years before the onset of hearing difficulty, for which he underwent subtotal gastrectomy with gastroduodenostomy and received 6 cycles of anticancer chemotherapy. Thus, it was deemed to be highly probable that the multiple lesions detected on the MRI scans were metastatic lesions. We performed positron emission tomography-computed tomography to investigate the presence of primary lesions at other sites; however, no additional hypermetabolic lesions or metastasis to other organs was detected (Fig. 4). We performed abdomino-pelvic computed tomography to establish recurrent gastric cancer at the primary site as part of the differential diagnosis, but this revealed no notable findings.

In order to excise the brain lesions and obtain a histopathologic diagnosis, craniotomy was performed and the tumor was removed via a retrosigmoid approach for the left internal carotid artery (ICA) lesions and those in the cerebellum. We identified a mucoid mass that was approximately 1 cm in diameter (Fig. 5) with intraoperative retraction of the cerebellar hemisphere, and observed that the eighth cranial nerve originated from the brain stem. We performed frozen section biopsy of the mucoid mass, which revealed a diagnosis of metastatic adenocarcinoma. In light of this diagnosis, we discontinued the surgical operation.

On histopathologic analysis, the cells were found to have peripheral nuclei. Further, there were abundant “signet-ring” cells and discohesive, pleomorphic malignant cells, with the central region of the cells filled with intracytoplasmic mucin vacuoles.

**Fig. 1.** On T1-weighted axial image (A) and a 3-dimensional fluid attenuated inversion recovery VISTA CE one (B), taken at the patient’s initial visit due to hearing difficulty, there are multiple enhanced lesions along the cisternal and canalicular segments of the bilateral vestibulocochlear nerves.

**Fig. 2.** On a 3-dimensional fluid attenuated inversion recovery VISTA CE image (A), there is an interval growth of enhanced areas along the cisternal and canalicular segments of the bilateral eighth nerves and the newly developed intense enhancement of the bilateral trigeminal nerves involving the cisternal segments and Meckel’s caves. In addition, on a 3-dimensional DRIVE axial image (B), there is a newly developed, circular enhancing area in the left medial cerebellum.

**Fig. 3.** The enhanced magnetic resonance image of the spine. On T1-weighted turbo spin-echo sagittal image (A) and axial image (B), there are multifocal enhanced lesions in the conus medullaris and cauda equine. These findings are suggestive of metastatic tumors.

**Fig. 4.** Positron emission tomography-computed tomography. On transverse image (A) of low-dose head CT, there are non-hypermetabolic multiple brain nodules. These findings are suggestive of benign lesion. In addition on torso maximal intensity projection coronal view image (B) of the whole body, there are no metastatic lesions in any other sites.
was 18 IU/L (normal range: 18–46 IU/L), and the white blood cell count was 4 mm$^3$ (normal range). Furthermore, no malignant cells were identified on CSF cytology.

Currently, chemotherapy or RT is the standard treatment for patients with LC, although these are performed as a palliative measure rather than as a cure, and the resultant patient outcomes are suboptimal\textsuperscript{14).} Patient prognosis is reported to be poor for LC arising from gastric cancer. Even in patients who underwent chemotherapy and RT following the diagnosis of LC, the mean survival has been reported to be only approximately 4–6 weeks\textsuperscript{3,4).} In 2011, Tomita et al.\textsuperscript{12) performed a retrospective analysis of 12 patients who were diagnosed with LC from gastric cancer. According to these authors, the mean survival for patients with LC was 18 IU/L (normal range: 18–46 IU/L), and the white blood cell count was 4 mm$^3$ (normal range). Furthermore, no malignant cells were identified on CSF cytology.

Currently, chemotherapy or RT is the standard treatment for patients with LC, although these are performed as a palliative measure rather than as a cure, and the resultant patient outcomes are suboptimal\textsuperscript{14).} Patient prognosis is reported to be poor for LC arising from gastric cancer. Even in patients who underwent chemotherapy and RT following the diagnosis of LC, the mean survival has been reported to be only approximately 4–6 weeks\textsuperscript{3,4).} In 2011, Tomita et al.\textsuperscript{12) performed a retrospective analysis of 12 patients who were diagnosed with LC from gastric cancer. According to these authors, the mean survival for patients with LC was 18 IU/L (normal range: 18–46 IU/L), and the white blood cell count was 4 mm$^3$ (normal range). Furthermore, no malignant cells were identified on CSF cytology.

Currently, chemotherapy or RT is the standard treatment for patients with LC, although these are performed as a palliative measure rather than as a cure, and the resultant patient outcomes are suboptimal\textsuperscript{14).} Patient prognosis is reported to be poor for LC arising from gastric cancer. Even in patients who underwent chemotherapy and RT following the diagnosis of LC, the mean survival has been reported to be only approximately 4–6 weeks\textsuperscript{3,4).} In 2011, Tomita et al.\textsuperscript{12) performed a retrospective analysis of 12 patients who were diagnosed with LC from gastric cancer. According to these authors, the mean survival for patients with LC was 18 IU/L (normal range: 18–46 IU/L), and the white blood cell count was 4 mm$^3$ (normal range). Furthermore, no malignant cells were identified on CSF cytology.

Currently, chemotherapy or RT is the standard treatment for patients with LC, although these are performed as a palliative measure rather than as a cure, and the resultant patient outcomes are suboptimal\textsuperscript{14).} Patient prognosis is reported to be poor for LC arising from gastric cancer. Even in patients who underwent chemotherapy and RT following the diagnosis of LC, the mean survival has been reported to be only approximately 4–6 weeks\textsuperscript{3,4).} In 2011, Tomita et al.\textsuperscript{12) performed a retrospective analysis of 12 patients who were diagnosed with LC from gastric cancer. According to these authors, the mean survival for patients with LC was 18 IU/L (normal range: 18–46 IU/L), and the white blood cell count was 4 mm$^3$ (normal range). Furthermore, no malignant cells were identified on CSF cytology.

Currently, chemotherapy or RT is the standard treatment for patients with LC, although these are performed as a palliative measure rather than as a cure, and the resultant patient outcomes are suboptimal\textsuperscript{14).} Patient prognosis is reported to be poor for LC arising from gastric cancer. Even in patients who underwent chemotherapy and RT following the diagnosis of LC, the mean survival has been reported to be only approximately 4–6 weeks\textsuperscript{3,4).} In 2011, Tomita et al.\textsuperscript{12) performed a retrospective analysis of 12 patients who were diagnosed with LC from gastric cancer. According to these authors, the mean survival for patients with LC was 18 IU/L (normal range: 18–46 IU/L), and the white blood cell count was 4 mm$^3$ (normal range). Furthermore, no malignant cells were identified on CSF cytology.
patients who underwent triple-treatment regimens [chemotherapy, whole brain RT, and ventriculoperitoneal (VP)–shunt operation] was more than 100 days longer that it was for those who received only chemotherapy or chemotherapy combined with whole brain RT, indicating that patients who undergo triple-treatment regimens achieve better outcomes. However, it is important to note that there are not many cases for which triple-treatment regimens have been administered. Therefore, although promising, the VP-shunt operation is not yet an established modality. Moreover, there are currently no standard treatment guidelines for LC. In the present case, the diagnosis of LC was based on the analysis of the surgical biopsy specimen. Ten days later, the patient underwent whole-brain RT. Two weeks after the initiation of RT, his mental status became stuporous, and the patient died 1 week after admission to the ICU.

**CONCLUSION**

This case report describes a patient who was diagnosed with LC from gastric cancer. To our knowledge, cases such as this are rare. The current case is notable not only because the patient presented at the outpatient clinic of our medical institution with chief complaints of hearing impairment rather than neurological deficits such as headache, nausea, or seizure, but also because the MRI findings were suggestive of vestibular schwannoma. On the basis of the clinical presentation and imaging findings, the current case seemed to be initially misdiagnosed. RT should have been treated much earlier with proper diagnosis for better prognosis. However, currently, there is no established treatment regimen or highly sensitive test with which a diagnosis of LC from gastric cancer can be made. In conclusion, our case highlights the importance of the development of new diagnostic and treatment regimens for delayed LC which originate from gastric cancer.

**References**

1. Bruna J, González L, Miró J, Velasco R, Gil M, Tortosa A, et al.: Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. *Cancer* 115: 381-389, 2009
2. Bulut G, Erden A, Karaca B, Göker E: Leptomeningeal carcinomatosis of gastric adenocarcinoma. *Turk J Gastroenterol* 22: 195-198, 2011
3. Chamberlain MC: Leptomeningeal metastasis. *Semin Neurol* 30: 236-244, 2010
4. Groves MD: New strategies in the management of leptomeningeal metastases. *Arch Neurol* 67: 305-312, 2010
5. Larson DA, Rubenstein JL, McDermott MW: Treatment of metastatic cancer in DeVita JVT, Hellman S, Rosenberg SA (eds): *Cancer: Principles and Practice of Oncology*, ed 7. Philadelphia: Lippincott Williams & Wilkins, 2005, p2333
6. Lisenko Y, Kumar AJ, Yao J, Ajani J, Ho L: Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. *Am J Clin Oncol* 26: 165-170, 2003
7. Oh SY, Lee SJ, Lee J, Lee S, Kim SH, Kwon HC, et al.: Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases. *World J Gastroenterol* 15: 5086-5090, 2009
8. Park KK, Yang SI, Seo KW, Kim YO, Yoon KY: A case of metastatic leptomeningeal carcinomatosis from early gastric carcinoma. *World J Surg Oncol* 10: 74, 2012
9. Pentheroudakis G, Pavlidis N: Management of leptomeningeal malignancy. *Expert Opin Pharmacother* 6: 1115-1125, 2005
10. Sandberg DI, Bilsky MH, Seowdieane MM, Bzdil J, Gutin PH: Ommina-ya reservoirs for the treatment of leptomeningeal metastases. *Neurosurgery* 47: 49-54; discussion 54-55, 2000
11. Shin HR, Jung KW, Won YJ, Kong HJ, Yim SH, Sung J, et al.: National cancer incidence for the year 2002 in Korea. *Cancer Res Treat* 39: 139-149, 2007
12. Tominita H, Yasui H, Boku N, Nakasu Y, Mitsuya K, Onozawa Y, et al.: Leptomeningeal carcinomatosis associated with gastric cancer. *Int J Clin Oncol* 17: 361-366, 2012
13. Tsukikawa T, Tsukamoto H, Itoh A, Andoh A, Sasaki M, Koyama S, et al.: Meningitis carcinomatosa originating from an alpha fetoprotein-producing gastric cancer. *Intern Med* 39: 223-227, 2000
14. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. *Cancer* 49: 759-772, 1982